

DAFTAR PUSTAKA

1. Muliawan H, Hartopo A, Dinarti L, Irnizarifika, Dewangga M, Yanni M et al. Pedoman Diagnosis dan Tatalaksana Hipertensi Pulmonal. Jakarta: Perhimpunan Dokter Spesialis Kardiologi Indonesia; 2021.
2. Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M et al. 2022 ESC / ERS Guidelines for The Diagnosis and Treatment of Pulmonary Hypertension. 2022;24.
3. Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, et al. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. *Am J Respir Crit Care Med*. 2021;203(12):1472–87.
4. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. 2019;155(3):565–86.
5. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, et al. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: A Descriptive Study from Single-Center Hospital Registry of Adult Congenital Heart Disease and Pulmonary Hypertension in Indonesia. *BMC Cardiovasc Disord*. 2020;20(1):1–11.
6. Utami M. Gambaran Karakteristik Pasien Hipertensi Arteri Pulmonal di RSUP DR. M. Djamil Padang Tahun 2017-2021. 2022;Universita:1–18.
7. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic Definitions and Updated Clinical Classification of Pulmonary Hypertension. *Eur Respir J*. 2019;53(1).
8. Al-Qazazi R, Lima PDA, Prisco SZ, Potus F, Dasgupta A, Chen KH, et al. Macrophage–NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2022;206(5):608–24.
9. Lattanzio M, Scelsi L, Golino M, Lattuada M, Raineri C, Turco A, et al. Assessment of Right Ventricle in Pulmonary Arterial Hypertension with Three-Dimensional Echocardiography and Cardiovascular Magnetic Resonance. *J Cardiovasc Med*. 2021;22(12):929–36.
10. Wei-Ting, C. Jhih-Yuan, S. Chon-Seng, H. Yu-Wen, L. Yi-Chen, C. et al. ESC Heart Failure 2021 Right Ventricular Expression of NT-proBNP Adds Predictive Value to REVEAL Score in. 2021. p. 8: 3082–3092.
11. Syamsi K, Hariyanto D, Herman RB. Korelasi Kadar NT- proBNP dengan Fungsi Fraksi Ejeksi Ventrikel Kiri pada Gagal Jantung Anak. *Sari Pediatr*. 2020;22(1):30.
12. Keranov S, Dörr O, Jafari L, Troidl C, Liebetrau C, Kriechbaum S, et al. CILP1 as a Biomarker for Right Ventricular Maladaptation in Pulmonary Hypertension. *Eur Respir J*. 2021;57(4):1–14.

13. Sugiyanto S, Sabarudin HA, Fatimah F, Budiati TA, Setiawan AN, et al. Current Situation of Magnetic Resonance Imaging Services in Indonesia. *J Med Imaging Radiat Sci*. 2022;53(4):S52.
14. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, et al. Guidelines for The Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23(7):685–713.
15. Tsipis, Angelos. Petropoulou E. Echocardiography in the Evaluation of the Right Heart. *US Cardiol Rev*. 2021.
16. Gorelova A, Berman M, Al Ghouleh I. Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension. *Antioxidants Redox Signal*. 2021;34(12):891–914.
17. Naeije R, Richter MJ, Rubin LJ. The Physiological Basis of Pulmonary Arterial Hypertension. *Eur Respir J*. 2022;59(6):1–20.
18. Condon DF, Nickel NP, Anderson R, Mirza S, De VA, et al. The 6th World Symposium on Pulmonary Hypertension: what's old is new. *F1000Research*. 2019;8:1–8.
19. Beshay S, Sahay S, Humbert M. Evaluation and Management of Pulmonary Arterial Hypertension. *Respir Med*. 2020;171(July):106099.
20. Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, et al. Sex and Gender in Pulmonary Arterial Hypertension. *Eur Respir Rev*. 2021;30(162).
21. Herlambang G, Widjaja SL, Hafidh Y, Salimo H. Hubungan Rasio Netrofil Limfosit dengan Hipertensi Arteri Pulmonal pada Anak dengan Penyakit Jantung Bawaan Asianotik. *Sari Pediatr*. 2019;21(2):96.
22. Hoeper MM, Pausch C, Grünig E, Klose H, Staehler G, et al. Idiopathic Pulmonary Arterial Hypertension Phenotypes Determined by Cluster Analysis from the COMPERA Registry. *J Hear Lung Transplant*. 2020;39(12):1435–44.
23. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric Pulmonary Arterial Hypertension: Updates on Definition, Classification, Diagnostics and Management. *Eur Respir J*. 2019;53(1).
24. Ishizuka M, Zou W, Whalen E, Ely E, Coleman RD, Lopez-Terrada DH, et al. Hereditary Pulmonary Arterial Hypertension Burden in Pediatrics: A Single Referral Center Experience. *Front Pediatr*. 2023;11(March):1–6.
25. Ramirez R, Pienkos S, Perez V ZR. Pulmonary Arterial Hypertension Secondary to Drugs and Toxins. 2021;19–38.
26. Kolaitis NA, Zamanian RT, de Jesus Perez VA, Badesch DB, Benza RL, Burger CD, et al. Clinical Differences and Outcomes Between Methamphetamine-Associated and Idiopathic Pulmonary Arterial Hypertension in The Pulmonary Hypertension Association Registry. *Ann Am Thorac Soc*. 2021;18(4):613–22.

27. Moccaldi B, De Michieli L, Binda M, Famoso G, Depascale R, Perazzolo Marra M, et al. Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. *Int J Mol Sci.* 2023;24(4).
28. Rabacal W, Schweitzer F, Rayens E, Tarantelli R, Whang P, Jimenez VC, et al. Statin Treatment Prevents the Development of Pulmonary Arterial Hypertension in A Nonhuman Primate Model of HIV-Associated PAH. *Sci Rep.* 2019;9(1):1–10.
29. Dardi F, Guarino D, Cennerazzo F, Ballerini A, Magnani I, Bertozzi R, et al. Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors. *J Clin Med.* 2023;12(10).
30. Chen IC, Dai ZK. Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from A Pediatric Cardiological Point Of View. *Acta Cardiol Sin.* 2015;31(6):507–15.
31. Sibomana JP, Campeche A, Carvalho-Filho RJ, Correa RA, Duani H, Pacheco Guimaraes V, et al. Schistosomiasis Pulmonary Arterial Hypertension. *Front Immunol.* 2020;11(December):1–18.
32. Yang-Zhi GH, Yi-Xuan W, Jing-Si M, Ruo-Nan L, Jia W, Tian-Yu L, et al. MicroRNAs and Their Regulators: Potential Therapeutic Targets In Pulmonary Arterial Hypertension. *Vascul Pharmacol.* 2023;153.
33. Hartopo AB, Dinarti LK. The Shared Pathogenesis of Pulmonary Artery Hypertension. *ACI (Acta Cardiol Indones.* 2018;4(1):22.
34. Lan N, Massam B, Kulkarni S, Lang C. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. *Diseases.* 2018;6(2):38.
35. Humbert M. Pulmonary Arterial Hypertension And Chronic Thromboembolic Pulmonary Hypertension: Pathophysiology. *Eur Respir Rev.* 2010;19(115):59–63.
36. D’Agostino A, Lanzafame LG, Buono L, Crisci G, D’Assante R, Leone I, et al. Modulating NO–GC Pathway in Pulmonary Arterial Hypertension. *Int J Mol Sci.* 2023;25(1):36.
37. Frost A, Badesch D, Gibbs JS, Gopalan D, Khanna D, Manes A, et al. Diagnosis of Pulmonary Hypertension. *Eur Respir J.* 2019;53(1):1–12.
38. Raina A, Humbert M. Risk Assessment in Pulmonary Arterial Hypertension. *Eur Respir Rev.* 2016;25(142):390–8.
39. Lang RM, Badano LP, Mor-Avi V, Afzalpoor J, Armstrong A, Ernande L, Flachskampf et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015;28:1–39.

40. Suling F. Hipertensi Arteri Pulmonalis. *Maj Kedokt FK UKI*. 2010;XXVII(4):173–83.
41. Sanz J, Sánchez-Quintana D, Bossone E, Bogaard HJ, Naeije R. Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019;73(12):1463–82.
42. Lluçia-Valldeperas A, de Man FS, Bogaard HJ. Adaptation and Maladaptation of the Right Ventricle in Pulmonary Vascular Diseases. *Clin Chest Med*. 2021;42(1):179–94.
43. Purwowiyoto SL, Effendi IK. Gagal Ventrikel Kanan Akut: Penegakan Diagnosis dan Manajemen Tatalaksana 1. *Med Alkhairaat J Penelit Kedokt Dan Kesehat*. 2023;5(2):57–70.
44. Wang JMH, Rai R, Carrasco M, Sam-Odusina T, Salandy S, Gielecki J, et al. An anatomical review of the right ventricle. *Transl Res Anat*. 2019;17(September):100049.
45. Stubbs H, MacLellan A, Lua S, Dormand H, Church C. The Right Ventricle Under Pressure: Anatomy And Imaging in Sickness and Health. *J Anat*. 2023;242(1):17–28.
46. Sanders JL, Maron BA. Physiology of the Normal Right Ventricle. *Encyclopedia of Respiratory Medicine*, Second Edition. Elsevier Inc.; 2021. 506–515 p.
47. Hameed A, Condliffe R, Swift AJ, Alabed S, Kiely DG, Charalampopoulos A. Assessment of Right Ventricular Function—a State of the Art. *Curr Heart Fail Rep*. 2023;20(3):194–207.
48. Bousseau S, Sobrano Fais R, Gu S, Frump A, Lahm T. Pathophysiology and New Advances in Pulmonary Hypertension. *BMJ Med*. 2023;2(1):e000137.
49. Anton VN, Richard C, Emmanuelle C, David G, Nicolas M, Olga M, et al. The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension. *JACC Cardiovasc IMAGING*. 2022;15:240–53.
50. Surkova E, Cosyns B, Gerber B, Gimelli A, La Gerche A, Ajmone Marsan N. The Dysfunctional Right Ventricle: the Importance of Multi-Modality Imaging. *Eur Heart J Cardiovasc Imaging*. 2022;23(7):885–97.
51. Tadic M, Cuspidi C. Right Ventricle in Arterial Hypertension: Did We Forget Something?. *J Clin Med*. 2022;11(21).
52. Ibrahim ESH, Bajwa AA, White RD. Assessment of Pulmonary Arterial Hypertension by Magnetic Resonance Imaging. *Tomography*. 2015;1(1):23–9.
53. Wu CC, Takeuchi M. Echocardiographic Assessment of Right Ventricular Systolic Function. *Cardiovasc Diagn Ther*. 2018;8(1):70–9.

54. Ryan JJ, Huston J, Kutty S, Hatton ND, Bowman L et al. Right Ventricular Adaptation and Failure in Pulmonary Arterial Hypertension. *Physiol Behav.* 2017;176(3):139–48.
55. Smolarek D, Gruchała M, Sobiczewski W. Echocardiographic Evaluation of Right Ventricular Systolic Function: The Traditional and Innovative Approach. *Cardiol J.* 2017;24(5):563–72.
56. Ji M, Wu W, He L, Gao L, Zhang Y, Lin Y, et al. Right Ventricular Longitudinal Strain in Patients with Heart Failure. *Diagnostics.* 2022;12(2).
57. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging. *Eur Heart J Cardiovasc Imaging.* 2015;16(1):1–11.
58. Romano MMD, Moreira HT, Schmidt A, Maciel BC, Marin-Neto JA. Imaging Diagnosis of Right Ventricle Involvement in Chagas Cardiomyopathy. *Biomed Res Int.* 2017;2017.
59. Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the Diagnosis and Management of Heart Failure. *Heart Fail Rev.* 2022;27(2):625–43.
60. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in both Clinical and Forensic Medicine. *Int J Mol Sci.* 2019;20(8):18–20.
61. Pradhan NM, Mullin C, Poor HD. Biomarkers and Right Ventricular Dysfunction. *Crit Care Clin.* 2020;36(1):141–53.
62. Novack ML ZM. Natriuretic Peptide B Type Test. *StatPearls;* 2023.
63. Kim HN, Januzzi JL. Natriuretic Peptide Testing in Heart Failure. *Circulation.* 2011;123(18):2015–9.
64. Paul MH, Liza D, Kevin MV, Mitch CJ, Sabrina M, Eric B, et al. Prognostic Value of Brain Natriuretic Peptides in Patients with pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. *Am Heart J.* 2022;250:34–44.
65. Samad M, Malempati S, Restini CBA. Natriuretic Peptides as Biomarkers: Narrative Review and Considerations in Cardiovascular and Respiratory Dysfunctions. *Yale J Biol Med.* 2023;96(1):137–49.
66. Abdullah A, Iqbal A, Ishtiaq W, Hussain SW, Qadeer A, Rasheed G. Diagnostic Utility of N-terminal pro-Brain Natriuretic Peptide and C-reactive Protein in Diagnosing Heart Failure in Patients with Acute Hypoxemic Respiratory Failure. *Cureus.* 2020;12(1):1–8.
67. Taylor CJ, Moore J, O'Flynn N. Diagnosis and Management of Chronic Heart Failure: NICE guideline update 2018. *Br J Gen Pract.* 2019;69(682):265–6.

68. Ha Manh T, Do Anh D, Le Viet T. Effect of Body Mass Index on N-terminal Pro-Brain Natriuretic Peptide Values in Patients with Heart Failure. *Egypt Hear J*. 2023;75(1):1–9.
69. Muscari A, Bianchi G, Forti P, Magalotti D, Pandolfi P, Zoli M. N-terminal pro B-type Natriuretic Peptide (NT-proBNP): a Possible Surrogate of Biological Age in the Elderly People. *GeroScience*. 2021;43(2):845–57.
70. Tim Riskesdas 2018. Laporan Riskesdas 2018 Nasional. Lembaga Penerbit Balitbangkes. 2018. p. hal 156.
71. The Asia-Pacific perspective : Redefining Obesity and its Treatment. 2000.
72. Kaufman DP, Basit H KS. Physiology Glomerular Filtration Rate. 2023.
73. Billett HH. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. 1990. 151 p.
74. Mccarthy BE, Mcclelland RL, Appleby DH, Moutchia JS. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension. *Chest*. 2022;162(2):436–47.
75. Ozpelit E, Akdeniz B, Sezgin D, Sevinc C, Tertemiz KC, Ozpelit ME, et al. Clinical and Hemodynamic Profiles of Elderly Patients with Pulmonary Arterial Hypertension: A Single Center, Prospective Study. *J Geriatr Cardiol*. 2017;14(1):20–7.
76. Arshad HB, Duarte VE. Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease. 2021;17(2).
77. Amelia P, Yoshepine GA, Tina CL, Tobing V, Vincent I. Association Between Type of Congenital Heart Disease with Child Growth And Development Status: A Cross-Sectional Study in Medan, Indonesia. *narra j*. 2023;15–20.
78. Zheng L, Yang Y, Zhao W, Yang H, Zhan H, Zhao Y, et al. Clinical Characteristics and Survival Analysis of Class I Pulmonary Arterial Hypertension. 2023;15(2):1476–84.
79. Bazmandegan G, Abbasifard M, Ostadebrahimi H, Gholamrezapour M, Kamiab Z. Positive Association Between Hemoglobin Concentration and Blood Pressure in Adults: A Cross-Sectional Study Based on Rafsanjan Cohort Study. *Int J Hypertens*. 2023;2023(Cvd).
80. Xanthouli P, Koegler M, Marra AM, Benjamin N, Fischer L, Eichstaedt CA, et al. Risk Stratification and Prognostic Factors in Patients with Pulmonary Arterial Hypertension and Comorbidities A Cross-Sectional Cohort Study with survival follow-up. *Respir Res*. 2020;21(1):1–11.
81. Radchenko GD, Botsiuk YA, Sirenko YM. Ventricular Function and Cardio-Ankle Vascular Index in Patients With Pulmonary Artery Hypertension. *Vasc Health Risk Manag*. 2022;18(November):889–904.

82. Nickel NP, O'Leary JM, Brittain EL, Fessel JP, Zamanian RT, West JD, et al. Kidney Dysfunction in Patients with Pulmonary Arterial Hypertension. *Pulm Circ.* 2017;7(1):38–54.
83. O'Leary JM, Assad TR, Xu M, Birdwell KA, Farber-Eger E, Wells QS, et al. Pulmonary Hypertension in Patients with Chronic Kidney Disease: Invasive Hemodynamic Etiology and Outcomes. *Pulm Circ.* 2017;7(3):674–83.
84. Syukria Agussalim A, Eka Fajar Maulana A, Putradana A, Marvia E. The Relationship between Hypertension and Chronic Kidney Failure in the North Lombok Regency General Hospital. *Res Serv Adm Heal Sains Heal.* 2022;3(2):53–8.
85. Hendriks PM, Van De Groep LD, Veen KM, Van Thor MCJ, Meertens S, Boersma E, et al. Prognostic Value of Brain Natriuretic Peptides in Patients with Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. *Am Heart J.* 2022;250:34–44.
86. Swerdlow RH, Burns JM KS. Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension. *Biochim Biophys Acta.* 2014;8(1842):1219–31.
87. Kjaergaard J, Iversen KK, Akkan D, Møller JE, Køber L V., Torp-Pedersen C, et al. Predictors of Right Ventricular Function as Measured by Tricuspid Annular Plane Systolic Excursion in Heart Failure. *Cardiovasc Ultrasound.* 2009;7(1):1–7.
88. Li Q, Zhang Y, Cui X, Lu W, Ji Q, Zhang M. Optimal Combination of Right Ventricular Functional Parameters Using Echocardiography in Pulmonary Arterial Hypertension. *ESC Hear Fail.* 2024;(107):2694–706.
89. Lewis RA, Durrington C, Condliffe R, Kiely DG. BNP/NT-probnp in Pulmonary Arterial Hypertension: Time for Point of Care Testing? *Eur Respir Rev.* 2020;29(156).
90. Yang C, Ma J, Guo L, Li B, Wang L, Li M, et al. NT-Pro-BNP and Echocardiography for the Early Assessment of Cardiovascular Dysfunction in Neonates with Sepsis. *Med (United States).* 2022;101(37):E30439.
91. Gan CT, Mccann GP, Marcus JT, Wolferen SA Van, Twisk JW, Boonstra A, et al. NT-proBNP Reflects Right Ventricular Structure and Function in Pulmonary Hypertension. 2006;28(6):1190–4.
92. Topyła-Putowska W, Tomaszewski M, Wysokiński A, Tomaszewski A. Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations. *J Clin Med.* 2021;10(15).
93. Baroncini LAV, Borges LJL, Camarozano AC, Carmo D de C, Darwich RZ, Fortunato Junior JA. Echocardiographic Correlation Between Right Ventricular Function and Left Atrial Volume. *Arq Bras Cardiol.* 2019;112(3):249–57.

94. Ploegstra MJ, Berger RMF. Prognostic Biomarkers in Pediatric Pulmonary Arterial Hypertension. *Cardiovasc Diagn Ther.* 2021;11(4):1089–101.
95. Peacock AJ, Noordegraaf AV. Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension. *Eur Respir Rev.* 2013;22(130):526–34.
96. Troisi F, Greco S, Brunetti ND et al. Right Heart Dysfunction Assessed with Echography, B-type Natriuretic Peptide and Cardiopulmonary Test in Patients with Chronic Heart Failure. *J Cardiovasc Med.* 2008;9:672–6.
97. Martínez-Quintana E, Marrero-Negrín N, Gopar-Gopar S, Rodríguez-González F. Right Ventricular Function and N-terminal pro-brain Natriuretic Peptide Levels in Adult Patients with Simple Dextro-transposition of the Great Arteries. *Echocardiography.* 2017;34(6):876–80.
98. Pfeiffer, S. Avian, A. Douschan, P. Foris, V. Olschewski A et al. Right Ventricular Tissue Doppler Echocardiography in Pulmonary Hypertension. *Eur Respir J.* 2018;52:PA3111.

